A retrospective audit of the triage process introduced for breast referrals received during the Covid-19 pandemic.

E. Mackender,R. Dave,D. Tudor,JR Harvey
DOI: https://doi.org/10.1016/j.clbc.2024.01.010
IF: 3.078
2024-01-22
Clinical Breast Cancer
Abstract:Purpose Due to restrictions on breast clinic appointments during the COVID-19 pandemic, a triage process was introduced for new patient referrals. The robustness of this process was examined by analysing the incidence of cancer diagnosis and wait times to treatment. Methods Patients were triaged by secondary care consultant surgeons to an urgent appointment if they had high-risk symptoms based on pre-specified guidelines e.g., a lump or previous cancer. Those with non-urgent symptoms were seen on a deferred basis. A retrospective audit of patients referred between March 23 rd and July 20 th 2020 was performed, to investigate incidence of cancer, concordance of primary and secondary care diagnosis, and the wait times to first appointment. Results Most patients with breast-related symptoms received a face-to-face appointment (69%) with a Primary Care Physician (PCP) or Nurse Practitioner (NP), with 544 (31%) having a telephone PCP/NP appointment. Of 2023 patients, 1461 were triaged by the receiving breast unit to an urgent appointment, 461 to a deferred appointment and 101 to a breast pain telephone clinic. A diagnosis of breast cancer was made in 111/1461 (7.6%), 5/461 (1.1%) and 0% in these triaged groups respectively, and the median wait time to first appointment was 14 days (range 1-94), 32 days (range 6-114) and 21 days (range 10-52, p<0.001). Conclusion The one-stop triage process was safe, with statistically fewer cancer diagnoses in patients allocated a deferred appointment, at a rate similar to that seen in a screening population.
oncology
What problem does this paper attempt to address?